F-star Therapeutics, Inc. (FSTX) financial statements (2022 and earlier)

Company profile

Business Address 35 PARKWOOD DRIVE
CAMBRIDGE, CB22 3AT
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments78,54918,52654,45547,63850,55524,730
Cash and cash equivalents78,54918,52628,70914,72423,64910,684
Short-term investments  25,74632,91426,90614,046
Receivables 443    
Prepaid expense 982    
Other undisclosed current assets6,1906,1143,5221,649580840
Total current assets:84,73926,06557,97749,28751,13525,570
Noncurrent Assets
Operating lease, right-of-use asset3,2812,7822,717
Property, plant and equipment8877892,2342,319687522
Long-term investments and receivables   16,804 752
Long-term investments   16,804 752
Intangible assets, net (including goodwill)33,66333,912    
Goodwill14,89814,926    
Intangible assets, net (excluding goodwill)18,76518,986    
Restricted cash and investments  234234484 
Other noncurrent assets45161351673535
Total noncurrent assets:38,28237,5445,22019,5241,2061,309
TOTAL ASSETS:123,02163,60963,19768,81152,34126,879
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,32214,0585,0514,2474,4343,501
Accounts payable3,0814,5972,2101,8801,7001,519
Accrued liabilities6,2419,4612,4382,3672,7341,982
Interest and dividends payable  403   
Deferred revenue 300 
Debt  355   
Business combination, contingent consideration, liability1,9072,080    
Other undisclosed current liabilities906539    
Total current liabilities:12,13516,9775,4064,2474,4343,501
Noncurrent Liabilities
Long-term debt and lease obligation2,7232,6222,869   
Operating lease, liability2,7232,6222,869
Liabilities, other than long-term debt1,694440271933127
Other liabilities  271933127
Business combination, contingent consideration, liability1,694440    
Other undisclosed noncurrent liabilities9,61257619,3698,51113,1286,333
Total noncurrent liabilities:14,0293,63822,2658,70413,1596,360
Total liabilities:26,16420,61527,67112,95117,5939,861
Stockholders' equity
Stockholders' equity attributable to parent96,85742,99435,52655,86034,74817,018
Common stock212211
Additional paid in capital176,80891,238161,924157,931113,98468,559
Accumulated other comprehensive loss(1,502)(1,077)(235)(5)(23)(7)
Accumulated deficit(78,451)(47,168)(126,165)(102,068)(79,214)(51,535)
Total stockholders' equity:96,85742,99435,52655,86034,74817,018
TOTAL LIABILITIES AND EQUITY:123,02163,60963,19768,81152,34126,879

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues21,16711,256   352
Revenue, net 352
Gross profit:21,16711,256   352
Operating expenses(51,881)(33,641)(33,021)(28,470)(21,253)(19,756)
Operating loss:(30,714)(22,385)(33,021)(28,470)(21,253)(19,404)
Nonoperating income (expense)(941)(849)1,25499936996
Investment income, nonoperating  1,25499936996
Other nonoperating expense(941)(849)    
Interest and debt expense(844) (542)   
Other undisclosed loss from continuing operations before equity method investments, income taxes (2,386)    
Loss from continuing operations before equity method investments, income taxes:(32,499)(25,620)(32,309)(27,471)(20,884)(19,308)
Other undisclosed income from continuing operations before income taxes844     
Loss from continuing operations before income taxes:(31,655)(25,620)(32,309)(27,471)(20,884)(19,308)
Income tax benefit3721    
Loss before gain (loss) on sale of properties:(31,283)(25,619)(32,309)(27,471)(20,884)(19,308)
Other undisclosed net income  8,2124,617  
Net loss:(31,283)(25,619)(24,097)(22,854)(20,884)(19,308)
Other undisclosed net income (loss) attributable to parent    (6,795)1,942
Net loss attributable to parent:(31,283)(25,619)(24,097)(22,854)(27,679)(17,366)
Other undisclosed net loss available to common stockholders, basic   (4,617)  
Net loss available to common stockholders, basic:(31,283)(25,619)(24,097)(27,471)(27,679)(17,366)
Interest on convertible debt 1,000    
Net loss available to common stockholders, diluted:(31,283)(24,619)(24,097)(27,471)(27,679)(17,366)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(31,283)(25,619)(24,097)(22,854)(20,884)(19,308)
Comprehensive loss:(31,283)(25,619)(24,097)(22,854)(20,884)(19,308)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(425)557(230)18(6,811)1,953
Comprehensive loss, net of tax, attributable to parent:(31,708)(25,062)(24,327)(22,836)(27,695)(17,355)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: